Building Wealth For Those Who Follow!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LJPC - Nice close hopefully we rise from here.
LJPC MIN target is 15$ with high of around 50$ .
Soon you'll be riding a boat above water!!
LJPC - Didn't they do an offering at 10.50?
If so , this is trading well below that .
LJPC - I just picked up another 1k shares here kei. 20-50$ analyst targets here with huge upside potential!
LJPC - Nice to see the CEO buying! I just picked up another 1000 shares here. Analyst price targets are 20 - 50$ a share. That's a huge potential gain :)
Institutional ownership up 15% this past quarter so apparently your dead wrong dude.
I'd suggest doing more research and less time posting.
MACK blowing up on news this morning!
Company getting impatient by the looks. Could go subpenny in a hurry once the dump gate opens up.
The pump started this morning with the 4 buys.
I think the "K" was a fat finger hit. 77$ is what they meant.
I'm shocked that all those that were shouting, " this is going to 1$" aren't buying this up. Very strange ;)
With the 100 share taps coming in every hour or longer, it should only take 30 years to get this to 1.00.
Must be you've been talking to Big Mike.
I guess Big Mike couldn't convince one of his 8 ihub accounts to buy :)
Thought I read people were loading at the open?? Must be SSFT is the only stock that hasn't opened yet.
OPK - September 20, 2014 in Dublin, Ireland OPKO will present six month efficacy, safety, pharmacokinetic and pharmacodynamics data from the company’s advanced phase 2 trial for its long acting human growth hormone hGH-CTP (MOD-4023) in growth hormone deficient pediatric subjects.
ARWR ~ This is straight from the website.
Arrowhead and Shire are collaborating to develop and commercialize targeted peptide-drug conjugates (PDCs) using Arrowhead’s human-derived Homing Peptide platform and Shire’s therapeutic payloads. Arrowhead will receive research funding and is eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales.
Arrowhead and Shire are collaborating to develop and commercialize targeted peptide-drug conjugates (PDCs) using Arrowhead’s human-derived Homing Peptide platform and Shire’s therapeutic payloads. Arrowhead will receive research funding and is eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales.
Peptide Targeting
Arrowhead and Shire are collaborating to develop and commercialize targeted peptide-drug conjugates (PDCs) using Arrowhead’s human-derived Homing Peptide platform and Shire’s therapeutic payloads. Arrowhead will receive research funding and is eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales.
IT-101 (now CRLX-101)
Alnylam has received a license from Arrowhead to utilize their Dynamic Polyconjugate (DPC) delivery technology for an RNAi therapeutic product. Alnylam expects to deploy this technology for an undisclosed target in its "Alnylam 5x15" pipeline that is focused on genetically defined targets and diseases. Arrowhead is eligible to receive from Alnylam milestone payments and royalties on sales of product resulting from the license Less
Sentiment: Strong Buy
ARWR ~ Anyone know of any logical reason for this correction?
ARWR ~ Took advantage of the dip at 15.88
TGTX News out this morning. I'm mobile so can't cut and paste.
Totally agree. Happens so often that I almost sold after hours yesterday but was like , I'll ride it out and add the dip.
Not just bb stocks but all stocks.
Every time you post a chart on a stock I'm in you bring massive negative mojo the next day :(
They will give detailed results at the ASN in November for GCS -100 PH2A CKD.
They must have sniffed too much GLUU while writing that article. I love GLUU but don't see it going that high any time soon.
What a breath of fresh air your board is!! Nice to see a board that focuses on BB stocks and not a board over pumping Otc scam stocks!
Well done.
If you have an opportunity take a look at LJPC. I opened a position on Friday.
Indeed. . They have BLOCKBUSTER potential written all over them and apparently the analyst feel the same with the constant pps upgrades.
Targets from 25$ - 54$ is huge and it seems the targets keep rising! They just completed an offering at 10.50 for 56 million so they have plenty of funds for a while imo. I see 20$ coming sooner than later. Good luck :)
Interesting to see price targets on LJPC continue to climb. Anyone else researching this or have a position?
http://www.4-traders.com/LA-JOLLA-PHARMACEUTICAL-C-15488695/consensus/
LJPC ~ Grabbed a bunch on the dip under 10$. Thinking a huge move could be coming.
LJPC ~ Grabbed a bunch on the dip under 10$. Thinking a huge move could be coming.
LJPC - Took a starter on this dip. Looking good here.
Ummmm someone actually was dude. That was a copy and paste from an online research column about their current pipeline ..
So take your 10k comment and purchase some reading comprehension :)
TNXP - Some simple math - if Tonix stays independent and the FM, PTSD, and ETTH programs each generate $1 billion in annual sales in five years, the market could value Tonix at $30 billion.
Fully diluted, Tonix has 13 million shares now. Even at double that number of shares, Tonix would be valued at $1,153.85 per share, almost exactly 100 times its current share price. So we will put that in the "reasons to stay independent" column.
TNXP - Some simple math - if Tonix stays independent and the FM, PTSD, and ETTH programs each generate $1 billion in annual sales in five years, the market could value Tonix at $30 billion.
Fully diluted, Tonix has 13 million shares now. Even at double that number of shares, Tonix would be valued at $1,153.85 per share, almost exactly 100 times its current share price. So we will put that in the "reasons to stay independent" column.
TNXP - Anyone research this one? Looks like mega huge potential!
Wowza! ! And to think we're at the ground floor here! We're going to be the Jefferson 's soon and move'n on up to the deluxe apartment in the sky!! Weeeeeeee :)
This is just the beginning! If company pulls through, and I think they will , we have a legit retirement stock on our hands :)
SYN - Great news this morning. Big things coming imo:)
Ummmm , actually those that held didn't loose anything,,, no ? :)